Clarity Pharmaceuticals Ltd. is progressing three of its targeted copper theranostics through the clinic that are based on its sarcophagine technology that securely holds copper isotopes inside a cage-like structure, called a chelator. The SAR technology allows a unique pairing of copper isotopes, copper-64  and copper-67, for both cancer diagnosis and therapy.

A technology developed at the University of Birmingham, U.K., has been spun off as a potential treatment for ocular surface diseases. The platform technology from startup Healome Therapeutics Ltd. was developed by a team of material scientists at the University’s Healthcare Technologies Institute (HTI) that translates health technology concepts to products for clinical trials.

Pangea Biomed Ltd. picked up $7 million in seed financing to fast-track development of its multicancer, multitherapy response predictor Enlight. The platform combines machine learning and RNA sequencing to map tumor molecular signatures and predict how different cancer types will respond to oncology drugs. Pangea said instead of using transcriptomic data, it is utilizing ‘unsupervised’ AI techniques that harvest information about gene interactions.

LONDON – Oxford University spinout Oxdx Ltd. has raised £2.6 million (US$3.6 million) in pre-seed funding to advance development of a technology for directly identifying infectious pathogens without the need to purify, culture or amplify samples first. The instant testing method uses a mixture of a single universal reagent, high resolution microscopy and machine learning, to identify specific species and strains of bacteria, viruses and other pathogens within minutes.

The Royal Academy of Engineering in the U.K. has revealed a new batch of 70 entrepreneurs, including some developers of med-tech solutions, for its Leaders in Innovation Fellowships Global (LIF Global) program. This comes just two months after the LIF Advance edition of the initiative, which had 15 chosen. The selected entrepreneurs will receive equity-free support over the next six months from the training and mentorship program.

University of Edinburgh spinoff Biocaptiva Ltd. is taking its cell free DNA (cfDNA) capture device to clinical trials in 2022 following promising preclinical results. The company’s platform technology is designed to increase the quantity of cfDNA available for liquid biopsy testing. Current liquid biopsy practices obtain cfDNA via a venous blood draw but the concentration of tumor-derived ctDNA can be too low for comprehensive testing. Biocaptiva’ device emerged from research at the University of Edinburgh investigating liquid biopsy technologies.

Investors have backed a new precision medicine company targeting clonal hematopoiesis with $40 million. Tensixteen Bio Inc. is on a mission to understand how somatic mutations influence age-related diseases, including cancer. The San Francisco-based startup will use the funds to develop a genomics and clinical platform that can identify patients at high risk of developing disease.

Point-of-care (POC) diagnostics startup Chronus Health Inc. reeled in $22 million in a series A round led by Tarsadia Investments. The company plans to use the funds to scale its research, engineering and data science teams and hasten product and technology development. Monta Vista Capital, Sosv and Savantus Ventures also participated in the financings, along with an unidentified strategic investor.